Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Year: 2020
Type: conference-abstract
Source: Blood
Authors: Alfred L. Garfall, Saad Z. Usmani, María-Victoria Mateos, Hareth Nahi, Niels W.C.J. van de Donk, Jesus F. San-Miguel, Albert Oriol Rocafiguera, Laura Rosinol, Ajai Chari, Manisha Bhutani, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Jenna D. Goldberg, Arnob Banerjee, Amrita Krishnan
Institutions: Abramson Cancer Center, University of Pennsylvania, Levine Cancer Institute, Complejo Hospitalario de Salamanca, Karolinska University Hospital, Amsterdam UMC Location Vrije Universiteit Amsterdam, Clinica Universidad de Navarra, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Hospital Clínic de Barcelona, Icahn School of Medicine at Mount Sinai, City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3094996259